Aptose Biosciences (APTO) & GenVec (GNVC) Financial Survey
Aptose Biosciences (NASDAQ: APTO) and GenVec (NASDAQ:GNVC) are both biotechnology & medical research – nec companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.
This is a summary of recent recommendations for Aptose Biosciences and GenVec, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aptose Biosciences presently has a consensus price target of $7.00, indicating a potential upside of 241.46%. GenVec has a consensus price target of $7.00, indicating a potential downside of 2.64%. Given Aptose Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Aptose Biosciences is more favorable than GenVec.
Insider and Institutional Ownership
4.2% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 6.2% of GenVec shares are owned by institutional investors. 8.1% of GenVec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Aptose Biosciences and GenVec’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Aptose Biosciences and GenVec’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Aptose Biosciences||N/A||N/A||-$14.06 million||($0.78)||-2.63|
Aptose Biosciences is trading at a lower price-to-earnings ratio than GenVec, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences beats GenVec on 7 of the 9 factors compared between the two stocks.
About Aptose Biosciences
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company’s APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.